RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNα-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS

被引：12
|
作者：
Everson, G. [1 ]
Cooper, C. [2 ]
Hezode, C. [3 ]
Shiffman, M. L. [4 ,5 ]
Yoshida, E. [6 ]
Beltran-Jaramillo, T. [7 ]
Ferenci, P. [8 ]
Zeuzem, S. [9 ]
Brunda, M. [10 ]
Shulman, N. [11 ]
Navarro, M. [11 ]
Voulgari, A. [12 ]
Najera, I. [10 ]
Le Pogam, S. [10 ]
Yetzer, E. S. [11 ]
机构：
[1] Univ Colorado, Sch Med, Denver, CO USA
[2] Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada
[3] Univ Paris 12, Hop Henri Mondor, F-94010 Creteil, France
[4] Bon Secours Hlth Syst, Liver Inst Virginia, Richmond, VA USA
[5] Bon Secours Hlth Syst, Liver Inst Virginia, Newport News, VA USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] Asesor Dept Inmunoanalisis, Mexico City, DF, Mexico
[8] Med Univ Vienna, Vienna, Austria
[9] JW Goethe Univ Hosp, Frankfurt, Germany
[10] Roche, Nutley, NJ USA
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] Roche, Welwyn Garden City, England
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61189-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1177
引用
收藏
页码：S466 / S466
页数：1
相关论文
共 37 条
  • [31] SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN HIV-HCV G1 CO-INFECTED PATIENTS ACCORDING TO THE MAGNITUDE OF HCV RNA DECREASE AT WEEK 4 OF TREATMENT WITH PEGINTERFERON (PEGIFN) ALFA-2A (40KD) PLUS RIBAVIRIN (RBV) IN THE PARADIGM STUDY
    Sulkowski, Mark S.
    Slim, Jihad
    Sterling, Richard K.
    Hassanein, Tarek
    Sola, Ricard
    Serrao, Rosario
    Martorell, Claudia
    Bertasso, Anne
    Stancic, Saray
    Rodriguez-Torres, Maribel
    HEPATOLOGY, 2010, 52 (04) : 762A - 763A
  • [32] Deep-sequencing analysis of baseline and on-treatment samples from HCV genotype-1 patients treated for 5 days with TMC435 monotherapy and subsequently retreated with TMC435 in combination with PEG-IFN-α2a/ribavirin
    Lenz, O.
    Vijgen, L.
    Verbinnen, T.
    van Marck, H.
    Vandenbroucke, I.
    Peeters, M.
    De Smedt, G.
    Simmen, K.
    Fanning, G.
    Reesink, H.
    Picchio, G.
    ANTIVIRAL THERAPY, 2010, 15 : A27 - A27
  • [33] PHASE II RANDOMISED, PARTIALLY-BLIND, PARALLEL-GROUP STUDY OF ORAL DANOPREVIR (RG7227) WITH PEGIFNα-2A (PEGASYS®) PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHC: RESULTS OF PLANNED WEEK 12 INTERIM ANALYSIS OF THE ATLAS STUDY
    Terrault, Norah
    Cooper, Curtis
    Balart, Luis A.
    Larrey, Dominique G.
    Box, Terry D.
    Yoshida, Eric M.
    Lawitz, Eric
    Buggisch, Peter
    Ferenci, Peter
    Weltman, Martin
    Labriola-Tompkins, Emily
    Zhang, Ying
    Navarro, Mercidita T.
    Lim, Chin Yin
    Yetzer, Ellen S.
    Marcellin, Patrick
    HEPATOLOGY, 2010, 52 (04) : 335A - 336A
  • [34] NO COMPENSATORY FITNESS MUTATIONS SELECTED IN NS3/4A PROTEASE CLEAVAGE SITES DURING TREATMENT WITH TELAPREVIR, PEG-IFN-ALFA-2A, AND RIBAVIRIN IN PHASE II STUDIES OF TREATMENT-NAiVE HCV GENOTYPE 1-INFECTED PATIENTS
    Zhang, Eileen Z.
    Bartels, Doug J.
    Sullivan, James
    Marcial, Michelle
    Dorrian, Jennifer
    Tigges, Ann
    Kwong, Ann D.
    Kieffer, Tara L.
    HEPATOLOGY, 2008, 48 (04) : 1138A - 1138A
  • [35] PREDICTION OF SVR IN HCV GENOTYPE 1 PATIENTS CO-INFECTED WITH HIV BASED ON VIROLOGICAL RESPONSES AT WEEK 4 AND 12 OF TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®): RETROSPECTIVE ANALYSIS OF APRICOT
    Rodriguez-Torres, Maribel
    Rockstroh, Juergen
    Depamphilis, Jean
    Carosi, Giampiero
    Dieterich, Douglas T.
    Torriani, Francesca
    HEPATOLOGY, 2008, 48 (04) : 1137A - 1138A
  • [36] Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2A (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients:: Efficacy and safety analysis of the induction phase of the CHARIOT study
    Roberts, Stuart
    Weltman, Martin
    Crawford, Darrell
    Cheng, Wendy
    Sievert, William
    McCaughan, Geoffrey W.
    Desmond, Paul V.
    Yoshihara, Motoko
    Miller, John E.
    Depamphilis, Jean
    Marks, Pip
    Dore, Gregory J.
    HEPATOLOGY, 2007, 46 (04) : 257A - 258A
  • [37] HIGH RATES OF EARLY VIRAL RESPONSE, PROMISING SAFETY PROFILE AND LACK OF RESISTANCE-RELATED BREAKTHROUGH IN HCV GT 1/4 PATIENTS TREATED WITH RG7128 PLUS PEGIFN ALFA-2A (40KD)/RBV: PLANNED WEEK 12 INTERIM ANALYSIS FROM THE PROPEL STUDY
    Jensen, Donald M.
    Wedemeyer, Heiner
    Herring, Robert W.
    Ferenci, Peter
    Ma, Mang M.
    Zeuzem, Stefan
    Rodriguez-Torres, Maribel
    Bzowej, Natalie H.
    Pockros, Paul
    Vierling, John M.
    Ipe, David
    Hill, George Z.
    HEPATOLOGY, 2010, 52 (04) : 360A - 361A
1234